慢性乙型肝炎感染中血清Mac-2结合蛋白糖基化异构体（M2BPGi）

StephenW

Hepatol Int. 2019 Jan 22. doi: 10.1007/s12072-019-09928-5. [Epub ahead of print]
Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.
Mak LY1, Wong DK2,3, Seto WK4,5, Ning Q6, Cheung KS2, Fung J2,3, Lai CL2,3, Yuen MF7,8.
Author information

1
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Hong Kong, China. [email protected].
2
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Hong Kong, China.
3
    State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
4
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Hong Kong, China. [email protected].
5
    State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China. [email protected].
6
    Institute of Infectious Disease, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
7
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Hong Kong, China. [email protected].
8
    State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China. [email protected].

Abstract
BACKGROUND AND AIM:

Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum diagnostic marker for liver fibrosis in various liver diseases. We aimed to evaluate its role in assessment of liver fibrosis in chronic hepatitis B infection (CHB) with reference to liver stiffness measurement (LSM).
METHODS:

CHB patients with LSM by transient elastography technology and retrievable serum samples were recruited. Ten-year re-assessments of LSM and M2BPGi were repeated in a patient subgroup.
RESULTS:

240 CHB patients (M:F = 116:124; median age 47.5 years) were recruited. The median M2BPGi values for F0/F1/F2, F3 and F4 progressively increased with more advanced stages of liver fibrosis: 0.39, 0.46 and 0.82 COI, respectively (p < 0.01). M2BPGi levels correlated well with liver stiffness (r = 0.611), FIB-4 (r = 0.616), and strongly with APRI (r = 0.825) (all p < 0.001). Using cut-off values of 0.605 and 0.615 COI, the AUROCs were 0.754 and 0.799 for ≥ F3 and F4, respectively. M2BPGi identified one-quarter patients at risk of advanced fibrosis/cirrhosis otherwise classified into 'grey area' by LSM. In 86 patients with reassessment LSM, 21 (24.4%) showed significant fibrosis regression with corresponding decline in median M2BPGi level (- 0.11 COI) compared with the increase of +0.03 COI in patients without significant fibrosis regression (p = 0.011). Male gender, older age, use of potent antiviral therapy and change in serum M2BPGi were independently associated with significant fibrosis regression.
CONCLUSIONS:

Serum M2BPGi can risk-stratify CHB patients whose liver stiffness fell into the 'grey area'. Significant fibrosis regression occurring in one-quarter patients was reflected by a reduction in M2BPGi levels at 10-year interval.
KEYWORDS:

Cirrhosis; Elastography; Hepatitis B; Liver fibrosis; M2BPGi

PMID:
    30671807
DOI:
    10.1007/s12072-019-09928-5

StephenW

Hepatol Int。 2019年1月22日。土井：10.1007 / s12072-019-09928-5。 [印刷前的电子版]
慢性乙型肝炎感染中血清Mac-2结合蛋白糖基化异构体（M2BPGi）与肝硬度的相关性。
Mak LY1，Wong DK2,3，Seto WK4,5，Ning Q6，Cheung KS2，Fung J2,3，Lai CL2,3，Yuen MF7,8。
作者信息

1
    香港大学医学系，香港薄扶林道102号玛丽医院，香港。 [email protected]。
2
    香港大学医学系，香港薄扶林道102号玛丽医院，香港。
3
    香港大学肝脏研究国家重点实验室，中国香港。
4
    香港大学医学系，香港薄扶林道102号玛丽医院，香港。 [email protected]。
五
    香港大学肝脏研究国家重点实验室，中国香港。 [email protected]。
6
    华中科技大学同济医院传染病研究所，武汉
7
    香港大学医学系，香港薄扶林道102号玛丽医院，香港。 [email protected]。
8
    香港大学肝脏研究国家重点实验室，中国香港。 [email protected]。

抽象
背景和目的：

Mac-2结合蛋白糖基化异构体（M2BPGi）是用于各种肝病的肝纤维化的新型血清诊断标记物。我们旨在评估其在慢性乙型肝炎感染（CHB）肝纤维化评估中的作用，参考肝硬度测量（LSM）。
方法：

招募了通过瞬时弹性成像技术和可回收血清样品的LSM患者。在患者亚组中重复对LSM和M2BPGi的十年重新评估。
结果：

招募了240名CHB患者（男：F = 116：124;中位年龄47.5岁）。 F0 / F1 / F2，F3和F4的中值M2BPGi值随着肝纤维化的更晚期阶段逐渐增加：分别为0.39,0.46和0.82 COI（p <0.01）。 M2BPGi水平与肝硬度（r = 0.611），FIB-4（r = 0.616）和APRI（r = 0.825）（所有p <0.001）强烈相关。使用0.605和0.615 COI的截止值，对于≥F3和F4，AUROC分别为0.754和0.799。 M2BPGi确定四分之一患有晚期纤维化/肝硬化风险的患者，否则被LSM分类为“灰色区域”。在重新评估LSM的86名患者中，21名（24.4％）显示出显着的纤维化消退，中位M2BPGi水平（ -  0.11 COI）相应下降，而没有明显纤维化消退的患者中+0.03 COI增加（p = 0.011）。男性，年龄较大，使用有效的抗病毒治疗和血清M2BPGi的变化与显着的纤维化消退独立相关。
结论：

血清M2BPGi可以对肝硬度下降到“灰色区域”的CHB患者进行风险分层。四分之一患者发生明显的纤维化消退，这反映在10年间隔内M2BPGi水平的降低。
关键词：

肝硬化;弹性;乙型肝炎;肝纤维化; M2BPGi

结论：
    30671807
DOI：
    10.1007 / s12072-019-09928-5